BGB-283
(Synonyms:BGB-283)
目录号 : KG10706
CAS No. : 1446090-77-2
纯度 : 98%
BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
BGB-283 potently inhibits BRafV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRafV600E and EGFR mutation/amplification. In BRafV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation.
BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRafV600E mutation.
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
分子式 |
C25H17F3N4O3
|
分子量 |
478.42
|
CAS号 |
1446090-77-2
|
中文名称 |
BGB-283
|
储存方式 |
Store at -20°C
|